Anticancer drugs up-regulate HspBP1 and thereby antagonize the prosurvival function of Hsp70 in tumor cells

Susumu Tanimura1, A-i Hirano, Junya Hashizume

  • 1Laboratory of Cell Regulation, Department of Pharmaceutical Sciences, Graduate School of Biomedical Sciences, Nagasaki University, 1-14 Bunkyo-machi, Nagasaki 852-8521, Japan.

Insights

Heat shock protein 70 (Hsp70) aids tumor cell survival. Hsp70 binding protein 1 (HspBP1) antagonizes Hsp70, increasing cancer cell susceptibility to drug-induced death by promoting lysosomal membrane permeabilization.

Area of Science:

  • Molecular Biology
  • Cell Biology
  • Oncology

Background:

  • The 70-kDa heat shock protein (Hsp70) is upregulated in tumors, conferring resistance to chemotherapy.
  • Hsp70 binding protein 1 (HspBP1) modulates Hsp70 activity, but its role in cancer remains unclear.

Purpose of the Study:

  • To investigate if HspBP1 interferes with Hsp70's prosurvival function.
  • To determine HspBP1's role in sensitizing tumor cells to anticancer drugs.

Main Methods:

  • Analysis of HspBP1 and Hsp70 expression levels in normal and tumor cells.
  • Assessment of tumor cell susceptibility to anticancer drugs based on HspBP1/Hsp70 ratio.
  • Examination of HspBP1's effect on lysosomal membrane permeabilization and cathepsin release.
  • RNA interference to prevent HspBP1 upregulation.

Main Results:

  • Higher HspBP1/Hsp70 ratios correlated with increased drug susceptibility in tumor cells.
  • Ectopic HspBP1 expression enhanced drug sensitivity, dependent on HspBP1-Hsp70 binding.
  • Anticancer drugs upregulated HspBP1; blocking this upregulation reduced drug sensitivity.
  • HspBP1 overexpression promoted lysosomal permeabilization, cathepsin release, and caspase-3 activation.

Conclusions:

  • HspBP1 antagonizes Hsp70's prosurvival function.
  • HspBP1 sensitizes tumor cells to anticancer drugs by promoting cathepsin-mediated cell death.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...